Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Southwell, Amber L ^a,c   Bugg, Charles W ^a   Kaltenbach, Linda S ^b   Dunn, Denise ^b   Butland, Stefanie ^c   Weiss, Andreas ^d   Paganetti, Paolo ^d,e   Lo, Donald C ^b   Patterson, Paul H ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NOVARTIS PHARMA AG   (Switzerland)

^e AC IMMUNE SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; HUNTINGTIN; INTRABODY HAPP1; MUTANT PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; HUNTINGTON PROTEIN, MOUSE; IMMUNOGLOBULIN FRAGMENT; NERVE PROTEIN; NUCLEAR PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; EXON; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSOSOME; NONHUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN TARGETING; RAT; SEQUENCE ANALYSIS; UBIQUITINATION; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PROTEIN STABILITY; SOLUBILITY;

AMINO ACID SEQUENCE; ANIMALS; CALPAIN; EXONS; IMMUNOGLOBULIN FRAGMENTS; MICE; MUTANT PROTEINS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEIN STABILITY; SOLUBILITY;

EID: 79551645514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016676     Document Type: Article

References (33)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
2. Imarisio S, Carmichael J, Korolchuk V, Chen C-W, Saiki S, et al. (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412: 191-209.
3. Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27: 2803-2820.
4. Qin Z-H, Gu Z-L (2004) Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol Sin 25: 1243-1249.
5. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, et al. (2010) Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease. J Biol Chem 285: 8808-8823.
6. Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, et al. (2009) Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells. J Biol Chem 284: 10855-10867.
7. Majumder P, Raychaudhuri S, Chattopadhyay B, Bhattacharyya NP (2007) Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cell Mol Neurobiol 27: 1127-1145.
8. Todde V, Veenhuis M, van der Klei IJ (2009) Autophagy: Principles and significance in health and disease. BBA - Mol Basis Dis 1792: 3-13.
9. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. (2006) Cleavage at the caspase-6 site Is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125: 1179-1191.
10. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, et al. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279: 20211-20220.
11. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, et al. (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40: 121-127.
12. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, et al. (2009) IKK phosphorylates huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 187: 1083-1099.
13. Southwell AL, Patterson PH (2010) Antibody therapy in Neurodegenerative disease. Rev neurosci In press.
14. Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, et al. (2008) Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 28: 9013-9020.
15. Southwell AL, Ko J, Patterson PH (2009) Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease. J Neurosci 29: 13589-13602.
16. Verspurten J, Gevaert K, Declercq W, Vandenabeele P (2009) SitePredicting the cleavage of proteinase substrates. Trends Biochem Sci 34: 319-323.
17. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006.
18. Bennett MJ, Huey-Tubman KE, Herr AB, West AP, Ross SA, et al. (2002) A linear lattice model for polyglutamine in CAG-expansion diseases. PNAS 99: 11634-11639.
19. Mende-Mueller LM, Toneff T, Hwang S-R, Chesselet M-F, Hook VYH (2001) Tissue-Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of Enhanced Levels of N- and C-Terminal htt Fragments in Huntington's Disease Striatum. J Neurosci 21: 1830-1837.
20. Lo DC, McAllister AK, Katz LC (1994) Neuronal transfection in brain slices using particle-mediated gene transfer. Neuron 13: 1263-1268.
21. Kaltenbach LS, Bolton MM, Shah B, Kanju PM, Lewis GM, et al. (2010) Composite primary neuronal high-content screening assay for Huntington's disease incorporating non-cell-autonomous interactions. J Biomol Screen 15: 806-819.
22. Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, et al. (2009) Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease. Anal Biochem 395: 8-15.
23. Jansen LET, Black BE, Foltz DR, Cleveland DW (2007) Propagation of centromeric chromatin requires exit from mitosis. J Cell Biol 176: 795-805.
24. Colby DW, Garg P, Holden T, Chao G, Webster JM, et al. (2004) Development of a human light chain variable domain (VL) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Biol 342: 901-912.
25. Schilling B, Gafni J, Torcassi C, Cong X, Row RH, et al. (2006) Huntingtin phosphorylation sites mapped by mass spectrometry: modulation of cleavage and toxicity. J Biol Chem 281: 23686-23697.
26. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, et al. (2007) Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 16: 2600-2615.
27. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, et al. (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16: 61-77.
28. Schroder M, Kaufman RJ (2005) The mammalian unfolded protein response. Ann Rev Biochem 74: 739-789.
29. Ratovitski T, Nakamura M, D'Ambola J, Chighladze E, Liang Y, et al. (2007) Nterminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle 6: 2970-2981.
30. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, et al. (2004) SUMO modification of duntingtin and Huntington's disease pathology. Science 304: 100-104.
31. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, et al. (2009) Phosphorylation of Threonine 3: Implications for huntingtin aggregation and neurotoxicity. J Biol Chem 284: 29427-29436.
32. Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I (2009) Secondary Structure of Huntingtin Amino-Terminal Region. Structure 17: 1205-1212.
33. Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, et al. (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol advanced online publication.